Logo of ajhgLink to Publisher's site
Am J Hum Genet. 2004 Aug; 75(2): 330–337.
Published online 2004 Jun 18. doi:  10.1086/422827
PMCID: PMC1216068

A Missense Single-Nucleotide Polymorphism in a Gene Encoding a Protein Tyrosine Phosphatase (PTPN22) Is Associated with Rheumatoid Arthritis

Abstract

Rheumatoid arthritis (RA) is the most common systemic autoimmune disease, affecting ∼1% of the adult population worldwide, with an estimated heritability of 60%. To identify genes involved in RA susceptibility, we investigated the association between putative functional single-nucleotide polymorphisms (SNPs) and RA among white individuals by use of a case-control study design; a second sample was tested for replication. Here we report the association of RA susceptibility with the minor allele of a missense SNP in PTPN22 (discovery-study allelic P=6.6×10-4; replication-study allelic P=5.6×10-8), which encodes a hematopoietic-specific protein tyrosine phosphatase also known as “Lyp.” We show that the risk allele, which is present in ∼17% of white individuals from the general population and in ∼28% of white individuals with RA, disrupts the P1 proline-rich motif that is important for interaction with Csk, potentially altering these proteins' normal function as negative regulators of T-cell activation. The minor allele of this SNP recently was implicated in type 1 diabetes, suggesting that the variant phosphatase may increase overall reactivity of the immune system and may heighten an individual carrier’s risk for autoimmune disease.

Rheumatoid arthritis (RA [MIM 180300]) is characterized by immune cell–mediated destruction of the joint architecture and is two to three times more common in women than in men (Firestein 2003). A strong genetic component is indicated (Seldin et al. 1999; MacGregor et al. 2000), and genome scans have identified multiple regions linked to disease (Cornelis et al. 1998; Shiozawa et al. 1998; Jawaheer et al. 2001, 2003; MacKay et al. 2002; Fisher et al. 2003). Although interesting associations have been reported (Suzuki et al. 2003; Tokuhiro et al. 2003), only alleles at the HLA-DRB1 locus have consistently demonstrated both linkage and association (Seldin et al 1999).

To identify genes involved in genetic predisposition to RA, we performed a case-control association study (called “discovery study”) with assays for 87 putative functional SNPs (Botstein and Risch 2003) in RA candidate genes and/or linkage regions. The discovery study, consisting of 475 individuals with RA and 475 individually matched controls, was obtained by Genomics Collaborative, Inc. (GCI). Case samples were collected from throughout the United States, and they met the 1987 American College of Rheumatology (ACR) diagnostic criteria for RA. All case samples were from white individuals with an age at onset of RA of between 18 and 68 years and a positive rheumatoid factor of ⩾20 IU. Individuals with psoriasis, systemic lupus erythematosus (SLE), ankylosing spondylitis, or Reiter syndrome were excluded. Control samples were taken from a pool of healthy white individuals from the United States with no medical history of RA or of any of the autoimmune disorders listed above. A single control was matched to each case on the basis of sex, age (±5 years), and ethnicity (grandparental country/region of origin). All protocols and recruitment sites have been approved by national and/or local institutional review boards, and all subjects were enrolled with informed written consent.

We found association with the minor allele (T) of a missense SNP (R620W [rs2476601, 1858C→T]) in the protein tyrosine phosphatase non-receptor type 22 gene (PTPN22) (allele frequency 13.8% in cases, 8.8% in controls) (P=6.6×10-4, allelic odds ratio [OR] 1.65, 95% CI 1.23–2.20).

Replication in a second study (called the “replication study”) confirmed association. Cases in the replication study were obtained by the North American Rheumatoid Arthritis Consortium (NARAC) and consisted of members of white multiplex families. For this study, DNA was available for 840 individuals with RA from 463 families. These families were recruited from throughout the United States through the 12 participating recruitment centers of NARAC (NARAC Web site). Informed written consent was obtained from every subject, including all participating family members, and the local institutional review board’s approval was secured at each recruitment site. The enrollment criteria for family participation are described in detail elsewhere (Jawaheer et al. 2001). In brief, at least two siblings must satisfy the 1987 ACR criteria for RA, at least one sibling must have documented erosions on hand radiographs, and at least one sibling must have disease onset between the ages of 18 and 60 years. The presence of psoriasis, inflammatory bowel disease, or SLE was an exclusionary criterion for the sib pair. Controls were selected from 20,000 individuals who are part of the New York Cancer Project (NYCP), a population-based prospective study of the genetic and environmental factors that cause disease (New York Cancer Project Web site). Two control individuals were matched to a single randomly chosen affected sib on the basis of sex, age (birth decade), and ethnicity (grandparental country/region of origin). These 463 independent cases (referred to as “single sibs”) and their 926 matched controls were used for all analyses reported in this study, except where noted.

The association for single sibs was as follows: allele frequency 15.8% in cases and 8.7% in controls (P=5.6×10-8, allelic OR 1.97, 95% CI 1.55–2.50). An increase of the risk allele frequency was apparent when all affected siblings (n=840) were analyzed (allele frequency 16.8%). Genotypic analyses produced similar results, showing increased frequencies of both TT and TC genotypes in the cases, compared with the controls (table 1).

Table 1
Frequency of PTPN22 Genotypes in Individuals with RA and Matched Controls in Two Independent Sample Sets[Note]

We used contingency tables and conditional-logistic regression (CLR) (Breslow and Day 1980) to assess the association of the PTPN22 R620W genotype with RA (table 2). In the discovery study, both the TC (ORCLR 1.69, P=.0012) and TT (ORCLR 2.26, P value not significant) genotypes conferred an increased risk for disease compared with the CC genotype. Further adjustment for the HLA-DRB1 genotype, the strongest known genetic risk factor (Seldin et al. 1999), had little impact on risk estimates. Similar results were observed in the replication study. The susceptible TT and TC genotypes were strongly associated with rheumatoid factor–positive (RF+) disease, even after adjustment for the HLA genotype (P=.0197 in discovery study, P=.0005 in replication study) (table 3); however, there was no evidence for association with rheumatoid factor–negative (RF) disease. This interesting observation has been replicated in an additional cohort of patients with recent-onset RA (A. T. Lee and P. K. Gregersen, unpublished data). There was no consistent sex difference in association of the risk allele with RA (data not shown).

Table 2
Association of PTPN22 with RA
Table 3
Association of PTPN22 with RF+ and RF Disease

To evaluate putative modes of inheritance, we combined the two data sets and used the likelihood-ratio test (Breslow and Day 1980) on the basis of CLR models. Although we could exclude a recessive mode of inheritance (P<.0001), the data are consistent with either additive or dominant modes of inheritance. We also generated estimates of the population-attributable fraction (0.11 for discovery study [95% CI 0.05–0.17]; 0.16 for replication study [95% CI 0.10–0.21]) (Schlesselman 1982; Yang et al. 2003). However, these estimates should be interpreted with caution, since our cases were selected to have relatively severe disease and thus are not representative of the full clinical spectrum of RA.

PTPN22 is located on chromosome 1p13, ∼9 Mb centromeric to a microsatellite marker, D1S1631, that shows linkage to RA in the NARAC sib pairs (SIBPAL P=.0011) (Jawaheer et al. 2003) from which our replication study was drawn. Linkage analysis using Allegro (Gudbjartsson et al. 2000) yielded an insignificant LOD score of 0.15 for PTPN22 R620W in these sib pairs, indicating that R620W is not solely responsible for the linkage seen at D1S1631. We then conducted stratified analyses based on PTPN22 R620W genotypes of the probands. Among 7, 76, and 193 affected sib pairs for which the proband had the TT, TC, or CC genotype, respectively, the respective mean identity-by-descent–sharing values were 0.598, 0.505, and 0.486, and the respective nonparametric linkage (NPL) scores were 0.94, 0.35, and −0.46 (Allegro) (Gudbjartsson et al. 2000). These results suggested that R620W has a weak effect on the 1p13 linkage signal. Li et al. (2004) have recently shown that there is large variability in NPL scores when families are stratified by the genotype of a single, randomly selected sib, and they developed a program (Genotype-IBD Sharing Test [GIST]) in which families are weighted on the basis of the genotypes of all family members. GIST analysis that was conditional on the T allele indicated significant evidence for linkage (P<.0001). The apparent difference between the significance of the stratified analysis and the GIST results may reflect the increased power of the GIST algorithm, or, alternatively, the rarity of the TT genotype may lead to poor convergence of the GIST test statistic to the asymptotic distribution. Taken together, all these data suggest that, whereas the SNP may account for a small part of the linkage signal seen on 1p, it is clearly not responsible for the entire signal.

We also genotyped this SNP in several additional control populations (table 4). The observed frequency of the risk allele in 560 additional white subjects (8.4%) was consistent with results in our two RA control populations. When all three control data sets of whites (n=1,961) were combined, the T allele was present in 16.7% of individuals at an allele frequency of 8.7%. The T allele frequency was lower in 99 Mexican Americans (3.5%) and 409 African Americans (2.4%). This allele was not detected in 100 Han Chinese or 21 Africans. A Fisher's Exact Test showed that these differences in allele frequencies were highly significant (P<1×10-10). It will be important to expand these studies to determine whether presence of the T allele in the African American and Mexican American populations is due to admixture with whites.

Table 4
Frequency of the PTPN22 Risk Allele in Discovery and Replication Control Samples and Other Populations

PTPN22 encodes a 110-kD cytoplasmic protein tyrosine phosphatase that consists of an N-terminal phosphatase domain and a long C-terminal region containing several proline-rich motifs (Cohen et al. 1999). The mouse ortholog, PEP (encoded by the murine gene Ptpn8), has been shown to be a potent down-regulator of T-cell receptor–dependent responses through its association with the SH3 domain of Csk (Cloutier and Veillette 1999). Although PEP and PTPN22 are only 70% identical at the amino acid level (Cohen et al. 1999), overexpression data suggest PTPN22 may play a role similar to that of PEP (Hill et al. 2002). To confirm that PTPN22 functions as a negative regulator of T-cell activation, we used RNA interference (RNAi) to decrease expression in Jurkat cells and then measured the response to antigen-receptor stimulation. mRNA knockdown by two independent siRNAs increased T-cell receptor–dependent activation by approximately two-fold, as measured by an NF-κB-reporter response (fig. 1). This is consistent with recent results in PEP-deficient mice (Hasegawa et al. 2004). These animals have rather subtle phenotypic alterations in T-cell function, with enhanced activation of Lck and expansion of memory T cells, but apparently normal naive T-cell function.

Figure  1
PTPN22 knockdown by RNAi increases antigen-receptor signaling in Jurkat T-cell line. Knockdown and NF-κB transcriptional response after T-cell receptor stimulation for cells transfected with two control siRNAs (Scramble) and two PTPN22 siRNAs. ...

The first proline-rich domain (P1) of PEP binds the SH3 domain of the negative regulatory kinase Csk (Cloutier and Veillette 1996; Gregorieff et al. 1998). Bottini and colleagues (2004) have recently shown that the R620W SNP (which is located in P1) affects the binding of PTPN22 to Csk. We confirmed this finding by cotransfection of full-length cDNA clones for PTPN22 (R620 or W620) and Csk into 293T cells, followed by immunoprecipitation of PTPN22. Although both PTPN22 constructs were expressed at similar levels, 2.5–3-fold less Csk was coimmunoprecipitated by the W620 protein, relative to the R620 protein (fig. 2). These data suggest that the association of this missense SNP with RA may be due to the inability of the variant phosphatase to bind Csk and down-regulate T-cell activation.

Figure  2
Western blot showing Csk coimmunoprecipitation by the two HA-tagged PTPN22 proteins (R620 and W620) expressed in 293T cells. W620 decreases the affinity of PTPN22 for Csk. Increasing the amount of PTPN22 W620 expressed does not increase the amount of ...

Prior studies have suggested that PTPN22 is expressed primarily in hematopoietic tissues (Cohen et al. 1999: Hill et al. 2002; Chien et al. 2003), such as thymus, spleen, bone marrow, and peripheral blood mononuclear cells (PBMCs). We confirmed and extended these findings by examining numerous tissues and specific PBMC subsets by use of semiquantitative kinetic RT-PCR (fig. 3 and table A1 [online only]). Expression appeared to be largely confined to hematopoietic tissues and was present in all subtypes of normal human PBMCs tested, including resting CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells, monocytes, neutrophils, dendritic cells, and natural killer (NK) cells (fig. 3). However, there appears to be a hierarchy, with NK cells and neutrophils expressing the most PTPN22 message and B cells and CD4+ T cells expressing the least. These data raise the possibility that the association of PTPN22 with RA could also be a result of functional changes in these other cell types. In particular, monocytosis and monocyte activation are characteristic features of RA, and NK and NK-T cells may also be involved in the pathogenesis of RA (Kojo et al. 2001; Dalbeth and Callan 2002). As a consequence, a complete analysis of PTPN22 function in these cell populations will be required to fully elucidate the role of this protein in autoimmunity.

Figure  3
RNA expression profile of PTPN22. Expression of the PTPN22 major splice variant (GenBank accession number NM_015967) was determined by kinetic RT-PCR ...

Familial clustering of multiple autoimmune disorders in the same family is well documented, and first-degree relatives of RA probands have a significantly higher prevalence of type 1 diabetes (T1D [MIM 222100]) than the general population (Lin et al. 1998). In addition, genomewide scans for autoimmune diseases, in both mouse and human, show colocalization of susceptibility loci (Becker et al. 1998; Griffiths et al. 1999), suggesting a possible shared genetic basis for autoimmunity. The finding that the minor allele of the PTPN22 SNP reported here is also associated with T1D (Bottini et al. 2004) supports the hypothesis that there are common genetic variants that contribute to general immune dysregulation and susceptibility to autoimmunity (Marrack et al. 2001; Wandstrat and Wakeland 2001). It will be important to examine PTPN22 associations in a wide variety of autoimmune diseases and to determine its functional role in each disease. Although a common underlying mechanism for autoimmunity is tempting to postulate, given the expression of this molecule in many immunologically relevant cell types, the possibility remains that PTPN22 may act in different ways in different autoimmune diseases.

Acknowledgments

We are grateful to the patients with RA, the controls, and the collaborating clinicians, for participation in this study; members of the Celera Diagnostics High Throughput, Biomarker, and Computational Biology groups, for invaluable help; T. L. Bugawan and E. Trachtenberg, for HLA typing; R. Lundsten, M. Kern, H. Khalili, and A. Rodrigues-Brown, for database and sample management of the NARAC collection; J. Lemaire and S. Mahan, for database and sample management at GCI; and T. White, S. Broder, R. Zamoyska, X. Hu, S. Dalrymple, J. Buggy, K. Van Orden, M. Kale, and P. Young, for discussions and insightful comments on this manuscript. Collection of the NARAC cohort has been funded by a National Arthritis Foundation grant and the National Institutes of Health, acting through the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases (contracts N01-AR-7-2232 and R01-AR44222). These studies were performed in part in the General Clinical Research Center, Moffitt Hospital, University of California, San Francisco, with funds provided by the National Center for Research Resources (5 M01 RR-00079, U.S. Public Health Service). Support was also provided by the National Institutes of Health through grant HG02275.

Appendix A

Table A1

RNA Expression Levels of PTPN22 in Purified Normal Cell Populations, Tissues, and Transformed Cell Lines, Expressed as a Fold Change Relative to the Average of All Normal Tissues (Excluding Tumor Cell Lines and Purified Hematopoietic Cells)[Note]

Cell/Tissue TypeSourceFold Changea
Normal cells:
 NK cellsAllCells25.14
 NeutrophilsAllCells24.82
 CD8+ T cellsAllCells12.26
 Bone marrowClontech10.41
 MonocytesAllCells8.42
 PBMCsAllCells7.86
 Dendritic cellsAllCells7.81
 Pan T cellsAllCells6.85
 CD4+ T cellsAllCells5.21
 B cellsAllCells5.01
Tissues:
 AdiposeBioChain−2.21
 Adrenal glandClontech−4.98
 BladderClontech−2.64
 Whole brainClontech−14.27
 BrainClontech−37.66
 Brain (fetal)Clontech−12.84
 BreastStratagene−1.68
 BreastBioChain−1.98
 BreastClontech−5.35
 Breast (mammary gland)Clontech−1.82
 CervixAmbionND
 EsophagusBioChain−3.61
 HeartClontech−6.73
 Heart (aorta)Clontech−1.63
 Heart (diseased)Clontech−17.65
 Heart (diseased, post-infarction)Clontech−8.67
 Heart (pericardium)BioChain−1.56
 Heart (fetal)Clontech−22.25
 Intestine (large)Stratagene2.99
 Intestine (large, tumor)Stratagene−1.89
 Intestine (small)Clontech−1.62
 Intestine (small, ileum diseased)Stratagene2.54
 KidneyClontech−10.69
 Kidney (fetal)Clontech−15.79
 LiverClontech−2.59
 Liver (fetal)Clontech−4.96
 LungStratagene4.18
 Lung (tumor)Clontech−1.07
 Muscle (skeletal)Clontech−17.45
 Muscle (skeletal)Ambion−23.81
 OvaryStratagene−1.15
 Ovary (tumor)Clontech−8.28
 PancreasBioChain−3.34
 PlacentaClontech−5.43
 ProstateStratagene−1.61
 ProstateClontech−132.45
 Salivary glandClontech−17.23
 Spinal cordClontech−4.75
 Spleen (fetal)Clontech−1.13
 StomachBioChain−2.16
 Stomach (tumor)Clontech−1.87
 TestisClontech−3.08
 ThymusClontech1.29
 Thymus (fetal)Clontech4.75
 Thyroid (female)Stratagene3.61
 ThyroidStratagene3.41
 ThyroidClontech−4.13
 TonsilClontech−1.17
 TrachaeClontech−2.19
 Umbilical cord (fetal)BioChain−1.37
 UterusClontech−8.95
Transformed cell lines:
 JurkatAmbion9.45
 HL60Ambion8.66
 K562Ambion1.28
 K562 (PMA treated)Stratagene−1.28
 K562Stratagene−4.33
 PC3 (prostate carcinoma)Ambion−15.1
 HeLa S3Clontech−24.81
 A431 (epidermal carcinoma)AmbionND
 HeLa S3AmbionND

Note.— ND = not detected.

aExpression of the PTPN22 major splice variant was determined by kinetic RT-PCR analysis. Each RNA sample was also amplified with seven housekeeping genes, as described elsewhere (Rogge et al. 2000). The level of expression of these housekeeping genes was used to normalize the amount of message in all samples. The normalized expression levels of PTPN22 in all normal tissues (excluding tumor cell lines and purified hematopoietic cells) were averaged, and the results from each individual sample were expressed as a fold change relative to this average. A positive number indicates more PTPN22 message in the indicated sample relative to the average of all samples, whereas a negative number means there is less PTPN22 message relative to the overall average.

Electronic-Database Information

The accession number and URLs for data presented herein are as follows:

GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for PTPN22 major splice variant [accession number NM_015967])
Genotype-IBD Sharing Test (GIST), http://phg.mc.vanderbilt.edu/GIST.shtml
New York Cancer Project, http://www.amdec.org
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for RA and T1D)

References

Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM (1998) Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 95:9979–9984 [PMC free article] [PubMed] [Cross Ref]10.1073/pnas.95.17.9979
Botstein D, Risch N (2003) Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet Suppl 33:228–237 [PubMed] [Cross Ref]10.1038/ng1090
Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS, Comings D, Mustelin T (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36:337–338 [PubMed] [Cross Ref]10.1038/ng1323
Breslow NE, Day NE (1980) Statistical methods in cancer research, volume I: the analysis of case-control studies. IARC Sci Publ 32:5–338 [PubMed]
Chien W, Tidow N, Williamson EA, Shih LY, Krug U, Kettenbach A, Fermin AC, Roifman CM, Koeffler HP (2003) Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway. J Biol Chem 278:27413–27420 [PubMed] [Cross Ref]10.1074/jbc.M304575200
Cloutier JF, Veillette A (1996) Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J 15:4909–4918 [PMC free article] [PubMed]
Cloutier JF, Veillette A (1999) Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 189:111–121 [PMC free article] [PubMed] [Cross Ref]10.1084/jem.189.1.111
Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM (1999) Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 93:2013–2024 [PubMed]
Cornelis F, Faure S, Martinez M, Prud’homme JF, Fritz P, Dib C, Alves H, et al (1998) New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA 95:10746–10750 [PMC free article] [PubMed] [Cross Ref]10.1073/pnas.95.18.10746
Dalbeth N, Callan MF (2002) A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 46:1763–1772 [PubMed] [Cross Ref]10.1002/art.10410
Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361 [PubMed] [Cross Ref]10.1038/nature01661
Fisher SA, Lanchbury JS, Lewis CM (2003) Meta-analysis of four rheumatoid arthritis genome-wide linkage studies: confirmation of a susceptibility locus on chromosome 16. Arthritis Rheum 48:1200–1206 [PubMed] [Cross Ref]10.1002/art.10945
Fries JF, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T, Bruce B (2002) HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 46:2320–2329 [PubMed] [Cross Ref]10.1002/art.10485
Germer S, Holland MJ, Higuchi R (2000) High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res 10:258–266 [PMC free article] [PubMed] [Cross Ref]10.1101/gr.10.2.258
Gregorieff A, Cloutier JF, Veillette A (1998) Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem 273:13217–13222 [PubMed] [Cross Ref]10.1074/jbc.273.21.13217
Griffiths MM, Encinas JA, Remmers EF, Kuchroo VK, Wilder RL (1999) Mapping autoimmunity genes. Curr Opin Immunol 11:689–700 [PubMed] [Cross Ref]10.1016/S0952-7915(99)00038-2
Gudbjartsson DF, Jonasson K, Frigge ML, Kong A (2000) Allegro, a new computer program for multipoint linkage analysis. Nat Genet 25:12–13 [PubMed] [Cross Ref]10.1038/75514
Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC (2004) PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303:685–689 [PubMed] [Cross Ref]10.1126/science.1092138
Hill RJ, Zozulya S, Lu YL, Ward K, Gishizky M, Jallal B (2002) The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp Hematol 30:237–244 [PubMed] [Cross Ref]10.1016/S0301-472X(01)00794-9
Iannone MA, Taylor JD, Chen J, Li MS, Rivers P, Slentz-Kesler KA, Weiner MP (2000) Multiplexed single nucleotide polymorphism genotyping by oligonucleotide ligation and flow cytometry. Cytometry 39:131–140 [PubMed] [Cross Ref]10.1002/(SICI)1097-0320(20000201)39:2<131::AID-CYTO6>3.3.CO;2-L
Jawaheer D, Li W, Graham RR, Chen W, Damle A, Xiao X, Monteiro J, Khalili H, Lee A, Lundsten R, Begovich A, Bugawan T, Erlich H, Elder JT, Criswell LA, Seldin MF, Amos CI, Behrens TW, Gregersen PK (2002) Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am J Hum Genet 71:585–594 [PMC free article] [PubMed]
Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Etzel C, Damle A, et al (2003) Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum 48:906–916 [PubMed] [Cross Ref]10.1002/art.10989
Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Monteiro J, Kern M, Criswell LA, Albani S, Nelson JL, Clegg DO, Pope R, Schroeder HW Jr, Bridges SL Jr, Pisetsky DS, Ward R, Kastner DL, Wilder RL, Pincus T, Callahan LF, Flemming D, Wener MH, Gregersen PK (2001) A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 68:927–936 [PMC free article] [PubMed]
Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T (2001) Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 44:1127–1138 [PubMed] [Cross Ref]10.1002/1529-0131(200105)44:5<1127::AID-ANR194>3.3.CO;2-N
Li C, Scott LJ, Boehnke M (2004) Assessing whether an allele can account in part for a linkage signal: the Genotype-IBD Sharing Test (GIST). Am J Hum Genet 74:418–431 [PMC free article] [PubMed]
Lin JP, Cash JM, Doyle SZ, Peden S, Kanik K, Amos CI, Bale SJ, Wilder RL (1998) Familial clustering of rheumatoid arthritis with other autoimmune diseases. Hum Genet 103:475–482 [PubMed] [Cross Ref]10.1007/s004390050853
MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30–37 [PubMed] [Cross Ref]10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B
MacKay K, Eyre S, Myerscough A, Milicic A, Barton A, Laval S, Barrett J, Lee D, White S, John S, Brown MA, Bell J, Silman A, Ollier W, Wordsworth P, Worthington J (2002) Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum 46:632–639 [PubMed] [Cross Ref]10.1002/art.10147
Marrack P, Kappler J, Kotzin BL (2001) Autoimmune disease: why and where it occurs. Nat Med 7:899–905 [PubMed] [Cross Ref]10.1038/90935
Rogge L, Bianchi E, Biffi M, Bono E, Chang SY, Alexander H, Santini C, Ferrari G, Sinigaglia L, Seiler M, Neeb M, Mous J, Sinigaglia F, Certa U (2000) Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet 25:96–101 [PubMed] [Cross Ref]10.1038/75671
Schlesselman JJ (1982) Case-control studies: design, conduct, analysis. Oxford University Press, New York
Seldin MF, Amos CI, Ward R, Gregersen PK (1999) The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 42:1071–1079 [PubMed] [Cross Ref]10.1002/1529-0131(199906)42:6<1071::AID-ANR1>3.0.CO;2-8
Shiozawa S, Hayashi S, Tsukamoto Y, Goko H, Kawasaki H, Wada T, Shimizu K, Yasuda N, Kamatani N, Takasugi K, Tanaka Y, Shiozawa K, Imura S (1998) Identification of the gene loci that predispose to rheumatoid arthritis. Int Immunol 10:1891–1895 [PubMed] [Cross Ref]10.1093/intimm/10.12.1891
Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K (2003) Functional haplotypes of PADI4 encoding citrullinating enzyme peptidylarginine deaminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395–402 [PubMed] [Cross Ref]10.1038/ng1206
Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, Furukawa H, Nagashima M, Yoshino S, Mabuchi A, Sekine A, Saito S, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K (2003) An intronic SNP in a RUNX1 binding site of SLC22A4 encoding an organic cation transporter is associated with rheumatoid arthritis. Nat Genet 35:341–348 [PubMed] [Cross Ref]10.1038/ng1267
Wandstrat A, Wakeland E (2001) The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2:802–809 [PubMed] [Cross Ref]10.1038/ni0901-802
Yang Q, Khoury MJ, Friedman JM, Flanders WD (2003) On the use of population attributable fraction to determine sample size for case-control studies of gene-environment interaction. Epidemiology 14:161–167 [PubMed] [Cross Ref]10.1097/00001648-200303000-00009

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics
PubReader format: click here to try

Formats:

Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

  • B cells take the front seat: Dysregulated B cell signals orchestrate loss of tolerance and autoantibody production[Current opinion in immunology. 2015]
    Jackson SW, Kolhatkar NS, Rawlings DJ. Current opinion in immunology. 2015 Apr; 3370-77
  • A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility[American Journal of Human Genetics. 2015]
    Carmona FD, Mackie SL, Martín JE, Taylor JC, Vaglio A, Eyre S, Bossini-Castillo L, Castañeda S, Cid MC, Hernández-Rodríguez J, Prieto-González S, Solans R, Ramentol-Sintas M, González-Escribano MF, Ortiz-Fernández L, Morado IC, Narváez J, Miranda-Filloy JA, Spanish GCA GroupMartínez-BerriochoaAgustínAUnzurrunzagaAinhoaAHidalgo-CondeAnaAMadroñero-VueltaAna B.ABFernández-NebroAntonioAOrdóñez-CañizaresM. CarmenMCEscalanteBegoñaBMarí-AlfonsoBegoñaBSopeñaBernardoBMagroCésarCRayaEnriqueEGrauElenaERománJosé A.JAde MiguelEugenioELópez-LongoF. JavierFJMartínezLinaLGómez-VaqueroCarmenCFernández-GutiérrezBenjamínBRodríguez-RodríguezLuisLDíaz-LópezJ. BernardinoJBCaminal-MonteroLuisLMartínez-ZapicoAleidaAMonfortJordiJTíoLauraLSánchez-MartínJulioJAlegre-SanchoJuan J.JJSáez-CometLuisLPérez-ConesaMercedesMCorbera-BellaltaMarcMGarcía-VillanuevaM. JesúsMJFernández-ContrerasM. EncarnaciónMESanchez-PernauteOlgaOBlancoRicardoROrtego-CentenoNorbertoNRíos-FernándezRaquelRCallejasJosé L.JLFanlo-MateoPatriciaPMartínez-TaboadaVíctor M.VM, Beretta L, Lunardi C, Cimmino MA, Gianfreda D, Santilli D, Ramirez GA, Soriano A, Muratore F, Pazzola G, Addimanda O, Wijmenga C, Witte T, Schirmer JH, Moosig F, Schönau V, Franke A, Palm Ø, Molberg Ø, Diamantopoulos AP, Carette S, Cuthbertson D, Forbess LJ, Hoffman GS, Khalidi NA, Koening CL, Langford CA, McAlear CA, Moreland L, Monach PA, Pagnoux C, Seo P, Spiera R, Sreih AG, Warrington KJ, Ytterberg SR, Gregersen PK, Pease CT, Gough A, Green M, Hordon L, Jarrett S, Watts R, Levy S, Patel Y, Kamath S, Dasgupta B, Worthington J, Koeleman BP, de Bakker PI, Barrett JH, Salvarani C, Merkel PA, González-Gay MA, Morgan AW, Martín J. American Journal of Human Genetics. 2015 Apr 2; 96(4)565-580
  • PTPN22: the archetypal non-HLA autoimmunity gene[Nature reviews. Rheumatology. 2014]
    Stanford SM, Bottini N. Nature reviews. Rheumatology. 2014 Oct; 10(10)602-611
  • The role of PTPN22 risk variant in the development of autoimmunity: Finding common ground between mouse and man[Journal of immunology (Baltimore, Md. : 195...]
    Rawlings DJ, Dai X, Buckner JH. Journal of immunology (Baltimore, Md. : 1950). 2015 Apr 1; 194(7)2977-2984
See all...

Links

  • BioAssay
    BioAssay
    PubChem BioAssay experiments on the biological activities of small molecules that cite the current articles. The depositors of BioAssay data provide these references.
  • Cited in Books
    Cited in Books
    NCBI Bookshelf books that cite the current articles.
  • ClinVar
    ClinVar
    Clinical variations associated with publication
  • Compound
    Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • Gene
    Gene
    Gene records that cite the current articles. Citations in Gene are added manually by NCBI or imported from outside public resources.
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence and PMC links.
  • GEO Profiles
    GEO Profiles
    Gene Expression Omnibus (GEO) Profiles of molecular abundance data. The current articles are references on the Gene record associated with the GEO profile.
  • HomoloGene
    HomoloGene
    HomoloGene clusters of homologous genes and sequences that cite the current articles. These are references on the Gene and sequence records in the HomoloGene entry.
  • MedGen
    MedGen
    Related information in MedGen
  • Nucleotide
    Nucleotide
    Primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • OMIM
    OMIM
    Genome Survey Sequence (GSS) nucleotide records reported in the current articles.
  • Protein
    Protein
    Protein translation features of primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...